Loading clinical trials...
Loading clinical trials...
A Multi-center, Phase Ia/Ib, Open Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma
This study is a multi-center, phase Ia/Ib, open clinical study to evaluate the safety, tolerability and pharmacokinetics of TWP-101 in patients with advanced melanoma and urothelial carcinoma. This study consists of two parts (Part A and Part B). Part A was a dose escalation study, and Part B was a dose expansion study.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Start Date
February 7, 2021
Primary Completion Date
October 31, 2022
Completion Date
December 31, 2022
Last Updated
July 23, 2021
76
ESTIMATED participants
TWP-101
DRUG
Lead Sponsor
Shandong TheraWisdom Biopharma Co., Ltd.
NCT05039801
NCT06066138
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions